AstraZeneca PLC (NASDAQ:AZN) Shares Bought by Focus Financial Network Inc.

Focus Financial Network Inc. raised its holdings in AstraZeneca PLC (NASDAQ:AZN) by 9.1% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 5,295 shares of the company’s stock after acquiring an additional 441 shares during the period. Focus Financial Network Inc.’s holdings in AstraZeneca were worth $412,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of the business. Oak Ridge Investments LLC raised its holdings in AstraZeneca by 7.2% in the 3rd quarter. Oak Ridge Investments LLC now owns 136,632 shares of the company’s stock valued at $10,645,000 after acquiring an additional 9,141 shares during the last quarter. US Bancorp DE grew its stake in shares of AstraZeneca by 6.9% in the 3rd quarter. US Bancorp DE now owns 232,419 shares of the company’s stock valued at $18,108,000 after buying an additional 14,965 shares during the period. HM Payson & Co. grew its stake in shares of AstraZeneca by 1,666.4% in the 3rd quarter. HM Payson & Co. now owns 65,514 shares of the company’s stock valued at $5,104,000 after buying an additional 61,805 shares during the period. Financial Advocates Investment Management grew its stake in shares of AstraZeneca by 1.3% in the 3rd quarter. Financial Advocates Investment Management now owns 14,960 shares of the company’s stock valued at $1,166,000 after buying an additional 198 shares during the period. Finally, First Trust Direct Indexing L.P. grew its stake in shares of AstraZeneca by 3.9% in the 3rd quarter. First Trust Direct Indexing L.P. now owns 33,059 shares of the company’s stock valued at $2,576,000 after buying an additional 1,246 shares during the period. Institutional investors and hedge funds own 20.35% of the company’s stock.

AstraZeneca Stock Performance

NASDAQ:AZN opened at $71.42 on Monday. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.69 and a current ratio of 0.89. The stock has a market capitalization of $221.44 billion, a P/E ratio of 34.50, a PEG ratio of 1.32 and a beta of 0.47. The company has a 50 day moving average price of $79.17 and a 200 day moving average price of $78.75. AstraZeneca PLC has a fifty-two week low of $60.47 and a fifty-two week high of $87.68.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on AZN. TD Cowen increased their price target on shares of AstraZeneca from $90.00 to $95.00 and gave the company a “buy” rating in a research note on Monday, August 12th. Deutsche Bank Aktiengesellschaft cut shares of AstraZeneca from a “hold” rating to a “sell” rating in a research note on Friday, September 13th. Finally, Erste Group Bank raised shares of AstraZeneca from a “hold” rating to a “buy” rating in a research note on Wednesday, September 11th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, seven have given a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $89.75.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.